

Alameda Alliance for Health
1240 South Loop Road
Alameda, CA 94502

Location: Cisco Webex,
Meeting ID: 2490 185 0395
Password: SzPYx7g35XD

IMPORTANT PUBLIC HEALTH AND SAFETY MESSAGE REGARDING PARTICIPATION AT ALAMEDA ALLIANCE FOR HEALTH COMMITTEE MEETINGS

STATE OR LOCAL OFFICIALS CONTINUE TO IMPOSE OR RECOMMEND MEASURES TO PROMOTE SOCIAL DISTANCING. AS A RESULT OF THE COVID-19 VIRUS, AND RESULTING ORDERS AND DIRECTION FROM THE PRESIDENT OF THE UNITED STATES, THE GOVERNOR OF THE STATE OF CALIFORNIA, AND THE ALAMEDA COUNTY HEALTH OFFICER, THE PUBLIC WILL NOT BE PERMITTED TO PHYSICALLY ATTEND THE ALAMEDA ALLIANCE FOR HEALTH MEETING TO WHICH THIS AGENDA APPLIES.

YOU MAY SUBMIT COMMENTS ON ANY AGENDA ITEM OR ON ANY ITEM NOT ON THE AGENDA, IN WRITING VIA MAIL TO “ATTN: ALLIANCE PHARMACEUTICAL AND THERAPEUTICS COMMITTEE” 1240 SOUTH LOOP ROAD, ALAMEDA, CA 94502; OR THROUGH E-COMMENT AT aasejo@alamedaalliance.org. YOU MAY WATCH THE MEETING LIVE BY LOGGING IN VIA COMPUTER AT THE FOLLOWING LINK: <https://alamedaalliance.webex.com/alamedaalliance> OR MAY LISTEN TO THE MEETING BY CALLING IN TO THE FOLLOWING TELEPHONE NUMBER: 1-408-418-9388. IF YOU USE THE LINK AND PARTICIPATE VIA COMPUTER, YOU MAY, THROUGH THE USE OF THE CHAT FUNCTION, REQUEST AN OPPORTUNITY TO SPEAK ON ANY AGENDIZED ITEM, INCLUDING GENERAL PUBLIC COMMENT. YOUR REQUEST TO SPEAK MUST BE RECEIVED BEFORE THE ITEM IS CALLED ON THE AGENDA. IF YOU PARTICIPATE BY TELEPHONE, YOU MAY SUBMIT ANY COMMENTS VIA THE E-COMMENT EMAIL ADDRESS DESCRIBED ABOVE OR PROVIDE COMMENT [DURING THE MEETING AT THE END OF EACH TOPIC](#).

PLEASE NOTE: THE ALAMEDA ALLIANCE FOR HEALTH IS MAKING EVERY EFFORT TO FOLLOW THE SPIRIT AND INTENT OF THE BROWN ACT AND OTHER APPLICABLE LAWS REGULATING THE CONDUCT OF PUBLIC MEETINGS, IN ORDER TO MAXIMIZE TRANSPARENCY AND PUBLIC ACCESS. DURING EACH AGENDA ITEM, YOU WILL BE PROVIDED A REASONABLE AMOUNT OF TIME TO PROVIDE PUBLIC COMMENT. THE COMMITTEE WOULD APPRECIATE, HOWEVER, IF COMMUNICATIONS OF PUBLIC COMMENTS RELATED TO ITEMS ON THE AGENDA, OR ITEMS NOT ON THE AGENDA, ARE PROVIDED PRIOR TO THE COMMENCEMENT OF THE MEETING.

AGENDA

ITEM VOTE	DESCRIPTION	TIME
I)	Call to order <i>Steve O’Brien, MD, Chief Medical Officer - Alameda Alliance</i>	
	<ul style="list-style-type: none"> Conflict of Interest Check/Disclosure Agenda Overview 	2 min -
II)	Informational Updates <i>Steve O’Brien, MD, Chief Medical Officer - Alameda Alliance</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i>	
	<ul style="list-style-type: none"> MediCalRx CalAIM initiative NCQA survey MCDAC (Medi-Cal Contract Advisory Committee) recommendations (10 drugs) 	15 min -

MCDAC Drug	Indication	MCDAC Drug Formulary Status	Action Based on - Safety, Efficacy, Essential Need, Misuse Potential, etc.	Previous MCAL Status
Apretude (cabotegravir extended-release injectable suspension) 600mg/3ml	PrEP HIV Prevention	F-PA	Leave As Is	Carve Out
Cosentyx (Secukinumab) 75mg/0.5ml prefilled syringe, 150mg/mL prefilled syringe, and 150mg/ml Sensoready pen	DMARD - Plaque Psoriasis, Ankylosing Spondylitis, Non-radiographic axial spondyloarthritis, Enthesitis-related arthritis	F-QL & AL	Recommend F-PA instead	F-PA
Dhivy (carbidopa/levodopa) 25-100mg tablet	Parkinson's Disease	F-AL	Recommend F-PA instead	F (generic) and NF (brand)
Endari (glutamine) 5 Gram powder packets	Sickle Cell Disease	F-PA	Leave As Is	NF
Ingrezza (valbenazine) 40mg, 60mg, 80mg capsules	Tardive Dyskinesia	F-PA	Leave As Is	NF (w/specific PA criteria)
Mavyret (glecaprevir/pibrentasvir) 50mg/20mg Pellet Packet	HCV genotype 1, 2, 3, 4, 5, or 6 infection in children 3 and up	F-PA & QL	Leave As Is	F-PA
Norditropin (somatropin) 5mg, 10mg, 15mg, and 30mg pens	Growth failure and Short-stature related conditions	F-PA per CDL	Recommend F-PA instead	NF (w/specific PA criteria)
Qulipta (atogepant) 10mg, 30mg, 60mg tablets	Episodic Migraine Prevention	F-PA	Leave As Is	NF
Verquvo (Vericiguat) 2.5mg, 5mg, 10mg tablets	Reduce Risk of Cardiovascular-related death and HF hospitalization	F-PA	Leave As Is	F-PA
Zimhi (naloxone hydrochloride injection)	Suspected Opioid Overdose	F-PA	Leave As Is	NF

III) Pharmacy Utilization Reports (Quarter 4, 2021)

Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance

- Top 50 Drugs by Cost
- Top 100 PA Reviewed Drugs

2 min -

ADJOURN TO CLOSED SESSION (Pursuant to California Government Code Title 5, §54954.5(h))

Discussion will Concern: Review and Recommendations to changes to the AAH Formulary and utilization management for selected drug classes

Estimated Date of Public Disclosure: 3/15/2022 (formulary changes only; no trade secrets will be disclosed).

IV) E-Voting Material/Consent Agenda

The following items have been sent to the voting committee for review via E-voting

Rahel Negash, PharmD, Pharmacist, Alameda Alliance

(All matters listed on the Consent Calendar are to be approved with one motion unless a member of the P&T Committee removes an item for separate action. Any consent calendar item for which separate action is requested shall be heard as the next Agenda item in closed session.)

10 min E
V

Monographs/Class Reviews	Changes
Skeletal Muscle Relaxants	• No changes
Oral iron preparations	• No changes
Direct Oral Anticoagulants	• No changes
Non-Opioid Antitussives/Expectorants	• No changes
Methergine monograph	• No changes
Medication Request Guidelines	Changes
Thrombocytopenia Agents	• Change "Rituxan" to rituximab

Long-Acting Muscarinic /Long-Acting Beta Agonist/ Corticosteroid inhaled Triple Combination Products	<ul style="list-style-type: none"> • Correct spelling of Breztri
Antifibrotic Respiratory Tract Agents	<ul style="list-style-type: none"> • Add clarifying language under chronic fibrosing interstitial lung diseases (ILD)
Oxbryta (voxelotor)	<ul style="list-style-type: none"> • Remove age restriction. Now indicated for children under 12 years
Synagis	<ul style="list-style-type: none"> • No changes
Corticosteroid Preparations to Treat Hemorrhoids	<ul style="list-style-type: none"> • No changes
Diuretics	<ul style="list-style-type: none"> • No changes
Antihypertensives	<ul style="list-style-type: none"> • No changes
Savella (milnacipran) tablet	<ul style="list-style-type: none"> • No changes
Travoprost (Travatan Z) ophthalmic	<ul style="list-style-type: none"> • No changes
Arikayce (amikacin)	<ul style="list-style-type: none"> • No changes
Tadalafil (Cialis) for BPH	<ul style="list-style-type: none"> • No changes
Estrogen Patches and Injectables	<ul style="list-style-type: none"> • No changes
Low Molecular Weight Heparins	<ul style="list-style-type: none"> • No changes
Elmiron (pentosane polysulfate	<ul style="list-style-type: none"> • No changes
Ezetimibe (Zetia)	<ul style="list-style-type: none"> • No changes
Altoprev (lovastatin ER) and Fluvastatin, Fluvastatin ER	<ul style="list-style-type: none"> • No changes
Symlin (pramlintide)	<ul style="list-style-type: none"> • No changes
Histamine H2 Receptor Antagonists	<ul style="list-style-type: none"> • No changes
Parkinson’s Disease Agents	<ul style="list-style-type: none"> • No changes
Linezolid	<ul style="list-style-type: none"> • No changes
Angiotensin II Receptor Blockers and Renin Inhibitors	<ul style="list-style-type: none"> • No changes
Pyridostigmine (Mestinon)	<ul style="list-style-type: none"> • No changes
Interim Formulary Updates	
<ul style="list-style-type: none"> • See p. XX in packet 	
Pharmacy Policy & Procedure Updates	
<ul style="list-style-type: none"> • RX-011 Decision and Notification Requirements 	<ul style="list-style-type: none"> • Update potential number of NOAs monitored each month for GC LOB
ED Oversight	
<ul style="list-style-type: none"> • No Updates 	
90 Day Maintenance List updates	
<ul style="list-style-type: none"> • No Updates 	
P&T Meeting Minutes	
<ul style="list-style-type: none"> • P&T Meeting Minutes Q4 December 21, 2021 	

V) New Business

Natalee Felten, PharmD, Pharmacist, PerformRx

- New MRG and PAD policies listed in each respective section below.

VI) Class Reviews, Monographs, and Recommendations

Natalee Felten, PharmD, Pharmacist, PerformRx

1. Inhaled Corticosteroid/ Long-Acting Beta Agonist (ICS/LABA) Combinations
2. First Generation Antihistamines
3. "New" Oral Medications for Heart Failure

VII) Medication Request Guidelines

Rahel Negash, PharmD, Pharmacist, Alameda Alliance

New:

1. Specialty Biological Agents for Nonradiographic Axial Spondyloarthritis (nr-axSpA)

Review:

2. Specialty Biological Agents for Crohn's Disease
3. Specialty Biological Agents for Ulcerative Colitis
4. Specialty Biological Agents for Rheumatoid Arthritis
5. Specialty Biological Agents for Psoriatic Arthritis (PsA)
6. Specialty Biological Agents for Psoriasis
7. Specialty Biological Agents for Polyarticular Juvenile Idiopathic Arthritis
8. Specialty Biological Agents for Ankylosing Spondylitis
9. Specialty Biological Agents for Hidradenitis Suppurativa
10. Specialty Biological Agents for Giant Cell Arteritis
11. Specialty Biological Agents for Uveitis
12. Specialty Biological Agents for FDA (if no indication specific criteria) and Non-FDA Approved Medically Accepted Indications - Retire
13. Agents for Atopic Dermatitis
14. PCSK-9 Inhibitors
15. Cystic Fibrosis Agents
16. Ophthalmic Antihistamines
17. Antibiotic Eye Medications
18. Pulmonary Arterial Hypertension (PAH) Criteria
19. Brilinta (ticagrelor) tablet
20. Xolair (omalizumab) for Asthma and Urticaria
21. Atovaquone (Mepron)
22. Fexofenadine-pseudoephedrine

45
min

V

VIII) Physician Administered Drug (PAD) Policies

Natalee Felten, PharmD, Pharmacist, PerformRx

New:

1. Specialty Biological Agents for Nonradiographic Axial Spondyloarthritis (nr-axSpA)
2. Emergency Use Authorization (EUA) Drugs/Products for COVID-19

Review:

3. Veklury
4. Anti-CD20 Monoclonal Antibodies (mAb)
5. Ophthalmic indications for bevacizumab
6. Immunoglobulin Therapy (IVIG)
7. Oxlumo (lumasiran)
8. Specialty Biological Agents for Crohn’s Disease
9. Specialty Biological Agents for Ulcerative Colitis
10. Specialty Biological Agents for Rheumatoid Arthritis
11. Specialty Biological Agents for Psoriatic Arthritis (PsA)
12. Specialty Biological Agents for Psoriasis
13. Specialty Biological Agents for Polyarticular Juvenile Idiopathic Arthritis
14. Specialty Biological Agents for Ankylosing Spondylitis
15. Specialty Biological Agents for Hidradenitis Suppurativa
16. Specialty Biological Agents for Giant Cell Arteritis
17. Specialty Biological Agents for Uveitis
18. Specialty Biological Agents for FDA (if no indication specific criteria) and Non-FDA Approved Medically Accepted Indications - Retire

10 min V

IX) Informational Updates on New Developments in Pharmacy

2 min

Natalee Felten, PharmD, Pharmacist, PerformRx

- New Product Review

X) Old Business

2 min

Natalee Felten, PharmD, Pharmacist, PerformRx

- Agents for Atopic Dermatitis MRG question from Q4 2021 P&T
- Erythropoiesis-Stimulating Agents MRG
- Erythropoiesis-Stimulating Agents PAD Guideline

Bibek Sandhu, PharmD, Pharmacist, PillarRx

- Comparison of CDL and our previous Medi-Cal formulary of Top 50 Drugs by Cost & Top 100 PA Reviewed Drugs

RECONVENE IN OPEN SESSION

XI) Public Comment

XII) Adjournment

- P&T Committee Member Forms

ACTION / FOLLOW-UP ITEMS		
ITEM	DUE DATE	RESPONSIBLE

FUTURE P&T MEETINGS	
NEXT MEETING	2021 P&T MEETINGS
June 15th, 2021	September 21st, 2021
	December 21st, 2021

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. If you wish to speak on a matter on the agenda, you will have the opportunity to do so in the order determined by the Chair. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

Note: Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Helen Lee at 510-747- 6241 or hlee@alamedaalliance.org at least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy the benefits of the meeting.